FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The formulation is backed by over 80 clinical trials and 200 scientific publications
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Consolidated revenue from operations stood at Rs. 111.05 crore
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Subscribe To Our Newsletter & Stay Updated